Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Hold” by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned an average rating of “Hold” from the eight analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.40.

Several research analysts have recently commented on KROS shares. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th.

Insider Transactions at Keros Therapeutics

In related news, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares in the company, valued at approximately $104,799.91. The trade was a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the sale, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,425 shares of company stock valued at $89,994. 12.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its stake in shares of Keros Therapeutics by 1,420.6% during the fourth quarter. SG Americas Securities LLC now owns 98,703 shares of the company’s stock worth $2,010,000 after buying an additional 92,212 shares during the period. JPMorgan Chase & Co. raised its holdings in Keros Therapeutics by 260.8% in the third quarter. JPMorgan Chase & Co. now owns 171,941 shares of the company’s stock valued at $2,720,000 after acquiring an additional 124,287 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Keros Therapeutics in the fourth quarter worth approximately $890,000. Y Intercept Hong Kong Ltd lifted its stake in Keros Therapeutics by 40.2% in the first quarter. Y Intercept Hong Kong Ltd now owns 164,483 shares of the company’s stock worth $1,816,000 after acquiring an additional 47,122 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in Keros Therapeutics during the 3rd quarter worth approximately $309,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $11.03 on Thursday. The company’s 50 day simple moving average is $10.92 and its 200-day simple moving average is $13.42. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55. The company has a market capitalization of $218.31 million, a price-to-earnings ratio of -3.66 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. Equities analysts expect that Keros Therapeutics will post -5.19 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.